EASD 2025 15 - 19 September 2025

Efficacy and hypoglycaemia outcomes of once-weekly IcoSema in type 2 diabetes according to pre-trial sodium-glucose cotransporter-2 inhibitor use: a post hoc analysis of COMBINE 1–3

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.

Keywords

Diabetes

Congress short oral presentation

Insulin

IcoSema (Icodec Semaglutide)

PHASE 3 (RCT)

Are you a healthcare professional?